Iambic Therapeutics, Inc. filed a Current Report on Form 8-K on November 16, 2026, announcing its financial results for the quarter ended September 30, 2026, and providing updates on its clinical pipeline and business partnerships.

The company reported that collaboration revenue for the third quarter of 2026 was $11.4 million, compared to $4.7 million during the same period in 2025. Year-to-date through September 30, 2026, collaboration revenue totaled approximately $24 million, while billings from collaborations were approximately $100 million.

Research and development expenses for the third quarter of 2026 were $34.1 million, up from $23.1 million in the prior year. General and administrative expenses were $7.4 million for the quarter, compared to $4.3 million in the prior year. The company reported a net loss of $38.5 million for the third quarter of 2026.

In terms of cash, Iambic reported cash and cash equivalents of $252 million as of September 30, 2026. Including net proceeds from its initial public offering (IPO) and upfront payments from AbbVie received in October 2026, the pro forma cash position was approximately $455 million.

The company highlighted several key developments in its pipeline:

On the partnership front, Iambic launched Enchant v3, a 41-billion-parameter transformer model for drug discovery, and signed new collaborations with Bayer and AbbVie. The company also achieved a program milestone in its collaboration with Takeda, triggering a $1.0 million payment.